ElectroCore Inc

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ElectroCore reports record revenue growth and strategic expansion plans

ElectroCore's Q1 2024 earnings call showcased impressive revenue growth, strong gross margins, and successful product launches, underlining the company's market resilience and innovation capabilities. With a focus on strategic expansion and profitability, ElectroCore is well-positioned for sustained growth and market leadership.
While facing challenges in managing R&D expenses and optimizing product returns, ElectroCore's commitment to operational efficiency and market diversification mitigates potential risks. The company's emphasis on employee contributions and customer relationships reinforces its competitive edge and customer loyalty.
By capitalizing on opportunities to expand product offerings, enter new markets, and drive innovation, ElectroCore can unlock significant growth potential and solidify its position as a key player in the neuromodulation industry. Navigating challenges through strategic decision-making and market differentiation will be crucial for ElectroCore's future success.

ElectroCore reports record revenue and margin growth in Q2 2024

ElectroCore's Q2 2024 earnings call showcased exceptional financial performance, marked by record revenue, improved margins, and a notable reduction in net loss.
The company's strengths lie in its revenue growth, product innovation, and solid financial position, while facing challenges in certain product sales and market competition.
Opportunities for ElectroCore include expanding product reach, exploring new therapeutic areas, and leveraging its strong cash position for strategic investments and growth.
Overall, ElectroCore's performance reflects resilience and potential for sustained growth in the healthcare industry, supported by a strong financial foundation and innovative product pipeline.

ElectroCore reports robust Q3 revenue growth, eyes VA channel expansion

ElectroCore Inc delivered strong revenue growth and improved financial performance in Q3 2024, driven by key product sales and customer expansion.
While facing challenges in certain product lines and overall net loss, the company's strategic focus on growth areas and cost management bode well for the future.
Opportunities in new purchase orders, VA channel expansion, and brand development position ElectroCore for continued success and market advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROCKAWAY, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Pro Medical Baltic UAB (“PMB”), whereby PMB will serve as the exclusive distributor of gammaCore Sapphire™ non-invasive vagus nerve stimulation (“nVNS”) to patients suffering from primary headache disorders in Lithuania, Latvia, Belarus, Kazakhstan and Ukraine.

electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe

BASKING RIDGE, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference.

electroCore to Present at the 13th Annual LD Micro Main Event Conference

electroCore's (ECOR) CEO Dan Goldberger on Q3 2020 Results - Earnings Call Transcript

Shares of electroCore (NASDAQ:ECOR) moved higher by 10.83% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 71.43% over the past year to ($0.10), which beat the estimate of ($0.14).

Recap: electroCore Q3 Earnings

On Thursday, November 12, electroCore (NASDAQ: ECOR) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

A Preview Of electroCore's Earnings

Conference Call to be Held at 4:30pm Eastern Time Conference Call to be Held at 4:30pm Eastern Time

electroCore to Announce Third Quarter Ended September 30, 2020 Financial Results on Thursday, November 12

ITP program providing reimbursement for gammaCore ™ extended to March. 31, 2021 with option for additional three years

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in England

BASKING RIDGE, N.J., Sept. 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Affairs has agreed to sponsor a quadruple blind, randomized, sham-controlled clinical trial of non-invasive vagal nerve stimulation (nVNS) in mild traumatic brain injury (mTBI) and Post-Traumatic Stress Disorder (PTSD). The trial is being sponsored by the Department of Veterans Affairs (VA) Office of Research and Development at the Atlanta VA Medical Center.

electroCore Announces Department of Veterans Affairs Sponsored Study of Non-Invasive Vagal Nerve Stimulation (nVNS) in Mild Traumatic Brain Injury (mTBI) and Post-Traumatic Stress Disorder (PTSD)

Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients

electroCore Announces Agreement with UpScript, LLC to be Exclusive Online Telehealth Provider for gammaCore Sapphire™ CV

BASKING RIDGE, N.J., Sept.  23, 2020  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive officer, will participate in a fireside chat at the JMP Securities MedTech Bio Summit, which is being held virtually October 1-2, 2020.

electroCore to Participate in the JMP Securities MedTech Bio Summit

BASKING RIDGE, N.J., Sept.  11, 2020  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held from September 14-16, 2020.

electroCore to Present at the HC Wainwright Virtual 22nd Annual Global Investment Conference

BASKING RIDGE, N.J., Aug.  27, 2020  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts1,” by Wittbrodt, Bremner et. al. in the journal Brain Stimulation.

electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)

Reimbursement for gammaCore™ in England Reimbursement for gammaCore™ in England

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

Rock-solid financial stats and a highly specific medical technology add up to a compelling argument in favor of ECOR stock.
The post Make ElectroCore a Core Holding after an Outstanding Q2 appeared first on InvestorPlace.

Make ElectroCore a Core Holding after an Outstanding Q2

electroCore, Inc's (ECOR) CEO Dan Goldberger on Q2 2020 Results - Earnings Call Transcript

Shares of electroCore (NASDAQ:ECOR) fell 3.1% in after-market trading after the company reported Q2 results.

Recap: electroCore Q2 Earnings

Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations

electroCore Announces Second Quarter Financial Results

electroCore to Announce Second Quarter Ended June 30, 2020 Financial Results on Thursday, August 13

Whether it’s all speculation or day trading, it seems there is no end to seeing major gains in small and micro-cap stocks that have positive announcements around anything to do with testing, vaccines, treatments or evebn cleaning products that can help win in the battle against COVID-19.

electroCore Rejoins Ranks of Exploding Speculative COVID-19 Stocks

Initial distribution to hospitals and patients expected to begin on July 31st Initial distribution to hospitals and patients expected to begin on July 31st

electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

Bioelectronic medicine's crucial role has come into focus with Covid-19, and a recent FDA approval practically assures ECOR stock's ascent.
The post FDA Green Light Makes ElectroCore a Micro-Cap to Watch appeared first on InvestorPlace.

FDA Green Light Makes ElectroCore a Micro-Cap to Watch

Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster headache and as an effective option for the treatment of migraine headache Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster headache and as an effective option for the treatment of migraine headache

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

BASKING RIDGE, N.J., July  16, 2020  (GLOBE NEWSWIRE) -- In a release issued under the same headline on July 14, 2020, the company’s cash was incorrectly stated as being as of the end of the first quarter. Note that the company ended the second quarter of 2020 with cash, cash equivalents and marketable securities of $18.9 million.

Correction - electroCore Provides Business Update and Select Financial Guidance

ElectroCore (ECOR) news for Monday concerning emergency authorization from the FDA for one of its drugs to treat coronavirus.
The post ElectroCore News: Why ECOR Stock Is Skyrocketing 142% Today appeared first on InvestorPlace.

ElectroCore News: Why ECOR Stock Is Skyrocketing 142% Today

Shares of electroCore Inc. ECOR, +142.94% more than doubled (up 155%) on very heavy volume in afternoon trading Monday, after the bioelectronic medicine company said it was issued an emergency use authorization (EUA) by the Food and Drug Administration OK'ing the use of its gammaCore Sapphire CV to help in the treatment of COVID-19 patients.

News for ElectroCore Inc Stock (ECOR)